Biotech Values

[BTH]

ARQL is a perfect example of a company that potentially has a good drug but has been screwed up badly by arrogant, buffoonery management/CEO and a partner with little experience in oncology drug development. Those two combinations are never a good thing - unless you just have a stroke of good luck following you.

So many of their trials are run on this old school chemotherapy "all comers" design, simply ignoring the new paradigm of personalized medicine. Given that c-Met is specific, if they even think about running future trials without a diagnostic or highly selected group, there is no reason to own ARQL, unless you like your chances as gambling. I really dont know if past trials designs were done as they were out of pure stupidity, laziness, arrogance, or greed...who knows.

Maybe shareholders will be lucky and someone will just buy these guys.

---- BTW, are you going to their Annual Shareholder Meeting? I think I might go; I want to ask Pucci some questions in front of the Board.